Los Angeles, USA , May 19, 2021 (GLOBE NEWSWIRE) -- Emerging Drugs for the Chemotherapy Induced Peripheral Neuropathy Treatment Will Soon Benefit Patients: A Focus on Recent Clinical Trials
Chemotherapy-Induced Peripheral Neuropathy Pipeline Report covers a complete clinical trials analysis of 15+ drugs and 15+ companies, which are developing therapies to change the treatment outlook.
DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy pipeline landscapes. It comprises CIPN pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chemotherapy Induced Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive CIPN pipeline products.
Some of the key takeaways of the Chemotherapy Induced Peripheral Neuropathy Pipeline Report
Get an overview of pipeline landscape @ CIPN Clinical Trials Analysis
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-dependent adverse effect of many frequently prescribed chemotherapy and biotherapy drugs, including taxanes, platinum-based drugs, vinca alkaloids, thalidomide, bortezomib, and interferon.
However, there are currently no approved drugs available to prevent or treat CIPN. Certain chemotherapy drugs are more likely to cause neuropathy. These include platinum drugs, such as oxaliplatin; taxanes, such as docetaxel; vinca alkaloids, such as vincristine; and myeloma treatments, such as bortezomib. Other chemotherapy drugs can also cause neuropathy.
Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs
PledOx (akacalmangafodipir, SP-04), being developed by Pledpharma (now Egetis Therapeutics AB), is a first in class drug candidate developed for the prevention of nerve damage caused by chemotherapy treatment in colorectal cancer patients.
Research and DevelopmentPhase III NCT03654729Phase III (POLAR-M): In October 2018, PledPharma initiated a Phase III, multicenter, double-blind, placebo-controlled study to establish the efficacious dose of PledOx in the prevention of chronic chemotherapy-induced peripheral neuropathy (CIPN) induced by oxaliplatin. This Phase III trial enrolled 291 participants and got completed in August 2020.
NCT04034355: Phase III (POLAR-A): In November 2018, PledPharm, in collaboration with Solasia Pharma, initiated a phase III, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent CIPN in the adjuvant treatment of patients with stage III or high-risk stage II colorectal cancer. A total of 301 participants were enrolled in this trial, and this trial was completed in August 2020.
ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), the company’s lead product candidate, represents a promising new treatment for severe sepsis with coagulopathy. ART-123 is a soluble recombinant human thrombomodulin. ART-123 inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug is currently in phase 2 of clinical trials for the treatment of Chemotherapy-induced Peripheral Neuropathy
Research and DevelopmentPhase IINCT04492436: In July 2021, Asahi Kasei Pharma will initiate a trial titled “A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo”. The aim of this study is to compare the efficacy and safety of ART-123 (low and high dose) to placebo on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy. The trial is expected to get completed by July 2024.
For further information, refer to the detailed report @ Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapeutics
Scope of CIPN Pipeline Drug Insight
Key Questions regarding Current Chemotherapy-Induced Peripheral Neuropathy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customised pipeline report @ Chemotherapy-Induced Peripheral Neuropathy Drugs Pipeline Report
Related Reports
DelveInsight's CIPN - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.
DelveInsight’s ‘Gene Therapy for Ocular Rare Disease -Market Insights, Competitive Landscape and Market Forecast - 2026’ report delivers an in-depth understanding of the disease.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.
DelveInsight’s Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease.
DelveInsight' s IgA Nephropathy (IgAN) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's IgG4-Related Disease- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
